Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Epigenetic profiling identifies markers of endocrine resistance and therapeutic options for metastatic castration-resistant prostate cancer

1 Jul 2025

Abstract excerpt

Androgen receptor (AR) signaling inhibitors, including enzalutamide, are treatment options for patients with metastatic castration-resistant prostate cancer (mCRPC), but resistance inevitably develops. Using metastatic samples from a prospective phase 2 clinical trial, we epigenetically profile enhancer/promoter activities with acetylation of lysine residue 27 on histone 3 (H3K27ac) chromatin immunoprecipitation...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Histone Deacetylase Inhibitors Research
Share to Prostate Cancer Treatment and Research
Share to Protein Degradation and Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40609538
DOI: 10.1016/j.xcrm.2025.102215

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Epigenetic profiling identifies markers of endocrine resistance and therapeutic options for metastatic castration-resistant prostate cancerPMID 40609538Read ↗

Integrative molecular analyses define correlates of high B7-H3 expression in metastatic castrate-resistant prostate cancerSemantic proximity Read ↗

Integrative molecular analyses define the genomic, transcriptomic, and epigenomic correlates of high B7-H3 expression in metastatic castrate-resistant prostate cancerSemantic proximity Read ↗

CREB5 reprograms FOXA1 nuclear interactions to promote resistance to androgen receptor-targeting therapiesSemantic proximity Read ↗

CREB5 reprograms nuclear interactions to promote resistance to androgen receptor targeting therapiesSemantic proximity Read ↗

Chromatin profiles classify castration-resistant prostate cancers suggesting therapeutic targetsSemantic proximity Read ↗

The mechanism of histone modifications in regulating enzalutamide sensitivity in advanced prostate cancerSemantic proximity Read ↗

Chromatin accessibility profiles of castration-resistant prostate cancers reveal novel subtypes and therapeutic vulnerabilitiesSemantic proximity Read ↗

Drug-induced epigenomic plasticity reprograms circadian rhythm regulation to drive prostate cancer towards androgen-independenceSemantic proximity Read ↗

Histone Deacetylases Are Required for Androgen Receptor Function in Hormone-Sensitive and Castrate-Resistant Prostate CancerSemantic proximity Read ↗

EP300/CREBBP acetyltransferase inhibition limits steroid receptor and FOXA1 signaling in prostate cancer cellsSemantic proximity Read ↗

Validation of histone deacetylase 3 as a therapeutic target in castration‐resistant prostate cancerSemantic proximity Read ↗

Epigenomic Regulation of Androgen Receptor Signaling: Potential Role in Prostate Cancer TherapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.